Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Ladiratuzumab vedotin |
Trade Name | |
Synonyms | SGN-LIV1A |
Drug Descriptions |
Ladiratuzumab vedotin (SGN-LIV1A) is an antibody-drug conjugate (ADC) comprised of an antibody targeting the zinc transporter LIV-1 linked to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to LIV1-positive cells, potentially resulting in inhibition of tumor growth (PMID: 25253783). |
DrugClasses | |
CAS Registry Number | 1629760-29-7 |
NCIT ID | C112001 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Ladiratuzumab vedotin | Atezolizumab Ladiratuzumab vedotin | 0 | 1 |
Ladiratuzumab vedotin | Ladiratuzumab vedotin | 0 | 2 |
Ladiratuzumab vedotin + Pembrolizumab | Ladiratuzumab vedotin Pembrolizumab | 0 | 1 |
Ladiratuzumab vedotin + Trastuzumab | Ladiratuzumab vedotin Trastuzumab | 0 | 1 |